Previous 10 | Next 10 |
Image source: The Motley Fool. Otonomy (NASDAQ: OTIC) Q4 2021 Earnings Call Feb 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Otonomy (OTIC) Q4 2021 Earnings Call Transcript
Otonomy, Inc. (OTIC) Q4 2021 Earnings Conference Call February 28, 2022, 4:30 PM ET Company Participants Dr. David Weber – President and Chief Executive Officer Paul Cayer – Chief Financial and Business Officer Robert Uhl – Managing Director Conference Call Participants S...
Otonomy press release (NASDAQ:OTIC): Q4 GAAP EPS of -$0.20 misses by $0.02. For further details see: Otonomy GAAP EPS of -$0.20 misses by $0.02
OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosing OTO-413 Phase 2a cohort in hearing loss fully enrolled with top-line results expected early in secon...
ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...
SAN DIEGO, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it will host a virtual Investor R&D Event from 10 a.m. - Noon ET on March 22, 2022. ...
OTO-313 Phase 2 trial is fully enrolled ahead of schedule Top-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovati...
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2021 and provide a corpo...
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two upcoming presentations on the OTO-413 hearing loss program at the 49 th Annual S...
Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceut...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...